Syneos Health Podcast | Psychedelics 3.0: Opportunities and Challenges in a Rapidly Evolving Field

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications.

Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy-Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments.

Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds.

For more from our neuroscience experts, check out these insights:

Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive Models

WEBINAR | Psychedelics 3.0: Challenges and Opportunities

Syneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical Development

BLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient’s Voice

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.